An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development

Area of Science:

• Oncology
• Molecular Biology
• Medical Imaging

Background:

• Developing targeted cancer therapies requires accurate in vivo models.
• Gastrointestinal stromal tumors (GISTs) often harbor c-KIT mutations.
• Imatinib is a targeted therapy for GISTs, but response mechanisms need further elucidation.

Purpose of the Study:

• To develop and validate an in vivo model for studying c-KIT-driven GISTs.
• To investigate the early metabolic effects of imatinib in responsive and resistant GIST models.
• To correlate positron emission tomography (PET) imaging findings with molecular and metabolic changes.

Main Methods:

• Established a murine FDC-P1 cell line model with specific c-KIT mutations (V560G responsive, D816V resistant).
• Utilized small animal PET imaging with fluorodeoxyglucose (FDG) to assess metabolic activity.
• Quantified glucose transporter (GLUT1) expression and glucose uptake in tumor cells.
• Evaluated cell viability and cytotoxicity under varying glucose conditions.

Main Results:

• FDG uptake significantly decreased within 4 hours in V560G tumors after imatinib treatment, unlike D816V tumors.
• GLUT1 expression and cell surface glucose transporter numbers reduced early in responsive tumors.
• In vitro studies showed decreased glucose uptake and enhanced imatinib cytotoxicity in low-glucose conditions.
• Metabolic changes preceded proliferation marker alterations and cell viability reduction.

Conclusions:

• The FDC-P1 model effectively recapitulates oncogene-dependent tumorigenesis and drug response.
• Early metabolic alterations, specifically reduced glucose uptake, are key indicators of imatinib response in GISTs.
• Metabolic effects likely contribute to the cytotoxic action of imatinib, explaining rapid PET imaging changes.
• This model serves as a valuable tool for developing and testing molecularly targeted anticancer therapies.